Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

14 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The mRNA levels of CD133 positive and CD133 negative cells after radiation exposure

ABSTRACT: The cancer initiating cells (CICs) act as a tumor initiation source. Recent studies have shown that CICs contribute to chemoresistance and radioresistance. The aims of this study were to investigate the relationship of CD133+ liver CICs and radiation resistance and to define a possible mechanism for radioresistance in hepatocellular carcinoma (HCC). Total RNA is obtained from CD133 positive cells and CD133 negative cells at 0, 12 and 24 hours after radiation exposure.

ORGANISM(S): Homo sapiens

SUBMITTER: Taek-Kyun Kim

PROVIDER: E-GEOD-22247 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

The mRNA levels of CD133 positive and CD133 negative cells after radiation exposure

Project description:The cancer initiating cells (CICs) act as a tumor initiation source. Recent studies have shown that CICs contribute to chemoresistance and radioresistance. The aims of this study were to investigate the relationship of CD133+ liver CICs and radiation resistance and to define a possible mechanism for radioresistance in hepatocellular carcinoma (HCC).

2013-07-20 | GSE22247 | GEO

Benign Uncultured CD133+ vs CD133-

Project description:6 benign TURP samples taken directly from patients were subjected to collagen digestion overnight. Epithelial cells isolated were adhered to collagen for 15 minutes. Adherent cells were passed through a magnetic bead column and cells positive for CD133 antibody were double selected. RNA was extracted from CD133+ and CD133- cells from each patient and amplified using the RiboAmp HS RNA amplification system. CD133+ (Cy5) and CD133- (Cy5) cDNA was hybridised to 30K cDNA array (CRUK facility) using the Invitrogen post labelling system. In each case that RNA was co-hybridised to a human pooled universal reference cDNA (Cy3). Keywords: repeat sample

2008-03-01 | GSE9935 | GEO

CD133+ and CD133- expression profiles of benign and HRPC cells

Project description:Epithelial cell cultures derived from benign and HRPC tissue biopsies were expanded in culture for 2-3 weeks. CD133+ and CD133- cells were isolated using the miltenyi magnetic bead system after adherence to collagen. CD133+ and CD133- RNA was isolated and amplified using the RiboAmp HS kit and expression profiling performed using the CRUK WGA gene set. Keywords: Tumour vs normal comparison

2008-03-01 | GSE9962 | GEO

CD133+ and CD133- CSC lines in primary human GBM

Project description:We cultured tumor cells from 22 GBM under medium conditions favoring the growth of neural stem cells. 11 out of 15 primary GBM contained a significant CD133+ subpopulation that comprised cells showing all hallmarks of neural stem cells. Cell lines derived from these CD133+ GBM showed a neurosphere-like, non-adherent growth pattern. In contrast, 4 out of 15 cell lines derived from primary GBM grew adherent in vitro and were driven by CD133- tumor cells that fulfilled stem cell criteria. In vivo, these GBM were characterized by a significantly lower proliferation index but similar GFAP staining as compared to CD133+ GBM. Gene arrays from 2x3 representative cells lines are given. Keywords: Cancer stem cell, CD133, glioblastoma

2007-03-06 | GSE7181 | GEO

Gene expression profiling of CD44-CD133+ and CD44+CD133+ Caco2 population

Project description:Gene expression profiling of CD44-CD133+ and CD44+CD133+ Caco2 population

2021-01-01 | GSE154750 | GEO

Comparison of gene expression between CD133+ and CD133- SW620 human colon cancer cells

Project description:CD133 has been widely used for identification and isolation of cancer stem cells in tumors although its role as a marker for cancer stem cell is still controversial . We isolated the CD133+ and CD133- cells from SW620 human colon cancer cell line and compared their biological characteristics, such as tumorigenicity,drug sensitivity, etc. Our study revealed that CD133+ SW620 cells were more tumorigenic and resistant to anti-cancer drugs. Correspondingly, they displayed different gene expression profile. However, it was observed that CD133- cells and CD133+ cells could mutually convert, indicating that CD133 expression was under dynamic and reversible regulations which might impose significant infulence on cells behaviors. Thus, our data challenge the role of CD133 as a marker for cancer stem cell.

2010-07-29 | GSE23295 | GEO

CD133+ vs. CD133- cells in GBML8, a primary glioblastoma tumorsphere culture

Project description:CD133+ and CD133- cells were FACS islated from GBML8 cells to find gene signatures upregulated in cancer stem cells

2016-10-25 | GSE85297 | GEO

Transcriptional profiling of CD133+/high vs CD133-/low cell populations of Caco2, HT-29 and HUH7 cell lines

Project description:Transcriptional profiling of CD133+/high vs CD133-/low cell populations of Caco2, HT-29 and HUH7 cell lines. Further in silico analysis of differentially expressed transcripts and proteins in CD133+/high vs CD133-/low cell populations revealed several potential key molecular regulators of CD133. In silico data was proved by CRISPR/CAS9 gene editing system.

2022-09-24 | E-MTAB-11779 | biostudies-arrayexpress

Y79 Rb Cell line: CD133 positive vs CD133 negative cancer stem like cells

Project description:Gene expression and pathway analysis of sorted CD133 negative and CD133 positive population

2018-05-17 | GSE96657 | GEO

Expression of FACS-sorted CD133+ and CD133- cells of three gastric cell lines

Project description:To identify the gene expression signature associated with CD133, the well-known stem cell markers, three gastric cancer cell lines were obtained (KATO-III, SNU201 and SNU601). Cultured gastric cancer celllines were sorted into CD133+ and CD133- population by FACS sorting and microarray-based gene expression profiling was performed.

2018-04-04 | GSE112631 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data